Xin Liu1, Thomas P Loughran. 1. Department of Medicine, Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-0850, USA. Xliu2@hmc.psu.edu
Abstract
PURPOSE OF REVIEW: Patients with chronic large granular lymphocyte (LGL) leukemia often have rheumatoid arthritis (RA), neutropenia and splenomegaly, thereby resembling the manifestations observed in patients with Felty's syndrome, which is a rare complication of RA characterized by neutropenia and splenomegaly. Both entities have similar clinical and laboratory presentation, as well as a common genetic determinant, HLA-DR4, indicating they may be part of the same disease spectrum. This review paper seeks to discuss the underlying pathogenesis and therapeutic algorithm of RA, neutropenia and splenomegaly in the spectrum of LGL leukemia and Felty's syndrome. RECENT FINDINGS: We hypothesize that there may be a common pathogenic mechanism between LGL leukemia and typical Felty's syndrome. Phenotypic and functional data have strongly suggested that CD3 LGL leukemia is antigen-activated. Aberrations in the T-cell repertoire with the emergence of oligoclonal/clonal lymphoid populations have been found to play a pivotal role in pathogenesis of RA. The biologic properties of the pivotal T cell involved in RA pathogenesis are remarkably similar to those in leukemic LGL. SUMMARY: RA-associated T-cell LGL leukemia and articular manifestations of typical Felty's syndrome are not distinguishable. A common pathogenetic link between LGL leukemia and RA is proposed.
PURPOSE OF REVIEW: Patients with chronic large granular lymphocyte (LGL) leukemia often have rheumatoid arthritis (RA), neutropenia and splenomegaly, thereby resembling the manifestations observed in patients with Felty's syndrome, which is a rare complication of RA characterized by neutropenia and splenomegaly. Both entities have similar clinical and laboratory presentation, as well as a common genetic determinant, HLA-DR4, indicating they may be part of the same disease spectrum. This review paper seeks to discuss the underlying pathogenesis and therapeutic algorithm of RA, neutropenia and splenomegaly in the spectrum of LGL leukemia and Felty's syndrome. RECENT FINDINGS: We hypothesize that there may be a common pathogenic mechanism between LGL leukemia and typical Felty's syndrome. Phenotypic and functional data have strongly suggested that CD3 LGL leukemia is antigen-activated. Aberrations in the T-cell repertoire with the emergence of oligoclonal/clonal lymphoid populations have been found to play a pivotal role in pathogenesis of RA. The biologic properties of the pivotal T cell involved in RA pathogenesis are remarkably similar to those in leukemic LGL. SUMMARY:RA-associated T-cell LGL leukemia and articular manifestations of typical Felty's syndrome are not distinguishable. A common pathogenetic link between LGL leukemia and RA is proposed.
Authors: Marcin W Wlodarski; Christine O'Keefe; Evan C Howe; Antonio M Risitano; Alexander Rodriguez; Ilka Warshawsky; Thomas P Loughran; Jaroslaw P Maciejewski Journal: Blood Date: 2005-05-24 Impact factor: 22.113
Authors: Nishant Dwivedi; Jagriti Upadhyay; Indira Neeli; Salar Khan; Debendra Pattanaik; Linda Myers; Kyriakos A Kirou; Bernhard Hellmich; Bryan Knuckley; Paul R Thompson; Mary K Crow; Ted R Mikuls; Elena Csernok; Marko Radic Journal: Arthritis Rheum Date: 2011-10-27
Authors: Ricardo Ruiz-Villaverde; Ahinoa Bueno-Rodriguez; Paula Aguayo-Carreras; Daniel Sánchez-Cano; Norberto Ortego-Centeno Journal: Sultan Qaboos Univ Med J Date: 2018-01-10
Authors: HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran Journal: Curr Hematol Malig Rep Date: 2020-04 Impact factor: 3.952
Authors: Jun Yang; Francis R LeBlanc; Shubha A Dighe; Cait E Hamele; Thomas L Olson; David J Feith; Thomas P Loughran Journal: Blood Date: 2018-04-26 Impact factor: 22.113